Today, Bumrungrad International Hospital Declares it is MERS-Free All Employees under Observation Return Home

Food and Healthcare Press Releases Thursday July 2, 2015 15:03
Bangkok--2 Jul--Bumrungrad International Hospital

Bumrungrad International Hospital announced today that the Department of Disease Control, under the Ministry of Public Health, has allowed all employees under observation at the hospital to return home. Thus, on July 2, 2015, there are no suspected cases of MERS-CoV at Bumrungrad and the hospital is MERS-Free.

The announcement of the first confirmed case of MERS-CoV in Thailand was made on June 18, 2015. Bumrungrad International Hospital was the one to detect the suspected MERS-CoV case and carried out its strict protocols for isolating and preventing the spread of the disease to other staff or patients, and safely transferred the patient for further treatment at the Bamrasnaradura Infectious Diseases Institute under the jurisdiction of the Ministry of Public Health, as per MoPH directions.

Bumrungrad also reported that it will continue to uphold its strict safety measures for the safety of its patients, visitors, employees, and the community. Examples include the Thermo Scan machines that measure body temperature, a Special Screening Clinic, and the addition of Airborne Infection Isolation rooms to screen patients who are in the high-risk group while preventing contamination with other patients; stricter and more frequent disinfection of floors and public equipment; close collaboration with the Department of Disease Control under the Ministry of Public Health to increase measures for monitoring and preventing MERS-CoV; and the management team constantly monitors the situation and meets with experts to adjust plans for dealing with the situation as appropriate.

Bumrungrad's strict protocols that have been practiced continuously has enabled the hospital to handle the situation correctly and quickly, garnering praise from the Ministry of Public Health, the Department of Disease Control, and Department of Health Service Support, and experts from various institutions, including the World Health Organization (WHO) and many news agencies.

Bumrungrad assures you that with the hospital's standard protocols and increased safety measures, meeting and even surpassing the guidelines of the World Health Organization (WHO) and the Central for Disease Control and Prevention (CDC) of the United States, it is confident in its ability to handle situations similar to these now and in the future.


Latest Press Release

Walgreens Boots Alliance and Microsoft establish strategic partnership to transform health care delivery

- Companies aim to improve health outcomes and lower overall costs with enhanced digital and retail experiences and an R&D commitment to build health care solutions through seven-year agreement Walgreens Boots Alliance Inc. (WBA) and Microsoft Corp....

Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems. (Logo:...

MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

MGI, established in 2016 as a subsidiary of global genomics leader BGI Group, announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's...

Gift of Life Donor Program is U.S. Leader in Saving Lives

For the 11th consecutive year, Gift of Life Donor Program is the nation's leading organ procurement organization (OPO), coordinating the most life-saving organs for transplant among all 58 U.S. OPOs. Gift of Life broke two national records in 2018,...

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Licensing rights are worldwide excluding US, Canada, Japan and South AmericaHelsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Menarini, an Italian biopharmaceutical Group active in 136 countries worldwide, today...

Related Topics